Expects Fourth Quarter Revenue Growth of Approximately 25% Year-Over-Year Expects Full Year 2025 Revenue of Approximately $380 Million
Collaboration will engage leading transplant clinician-scientists to study antibody-mediated rejection (AMR) and microvascular inflammation (MVI) using cellular-resolution profiling
CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
CareDx, Inc. (Nasdaq: CDNA) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT N ...
Third SHORE Publication Highlights HeartCare’s Role in Risk Stratification and Personalized Post-Transplant Care
CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare...
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value...
CareDx Extends Leadership in Kidney Transplant Molecular Testing with Launch of Unique Tissue-Based Gene Expression Assay – HistoMap Kidney
Total Revenue of $100 Million Increased 21% Year-Over-Year Grew Testing Services Volume to Approximately 50,300, Increase of 13% Year-Over-Year ...